Abstract. Several lines of direct evidence show that gliomas express high levels of vascular endothelial growth factor (VEGF). VEGF can promote the growth of gliomas through angiogenesis. It is believed that gliomas originate in the brain tumor stem cells (BTSCs). However, the direct effect of VEGF on the biological behavior of BTSCs has not been completely elucidated. In this study, we established C6 glioma stem cells (C6GSCs) from the C6 glioma cells. Furthermore, we suppressed the VEGF expression of C6GSCs using lentiviral vector-VEGF shRNA. After transfection, the VEGF expression of C6GSCs was downregulated significantly. The proliferation and invasion capacity of transfected C6GSCs was impaired and the ability of differentiation was enhanced. The data demonstrate that downregulation of VEGF expression attenuates malignant biological behavior of C6GSCs. RNA interference of VEGF expression implies an effective anti-gliomas strategy.
Introduction
Gliomas are the most common primary tumors originating in the central nervous system (CNS) (1) . They are graded from I to IV based on their degrees of malignancy. The grade IV glioblastoma (GB) is the most common and most malignant type of glioma which is highly invasive, and currently there exists no cure. This could in part be due to the existence of so-called brain tumor stem cells (BTSCs), a cellular subfraction within GB which contribute to recurrent tumor growth and resistance to drugs and irradiation (2) . BTSCs exhibit the ability to selfrenew as well as give rise to differentiated tissue cells, which are responsible for the progress of a tumor.
Several studies have shown that angiogenesis is essential for glioma growth and metastases (3, 4) . Vascular endotheli al growth factor (VEGF) is the most important stimulant factor in regulating angiogenesis. VEGF, a diffusible 36-46-kDa glycoprotein (5, 6) , and has been shown to be a potent mediator of brain tumor angiogenesis, vascular permeability and gliomas growth (7) . Several lines of direct evidence show that gliomas and BTSCs express high levels of VEGF (8) (9) (10) (11) . VEGF secreted by tumor cells interacts with VEGF receptors (VEGFRs) and stimulates downstream signaling molecules such as Akt and mitogen-activated protein kinases (MAPKs) to promote the migration, growth and survival of endothelial cells (12) (13) (14) .
VEGFRs include two tyrosine kinase receptors, VEGFR-1 and VEGFR-2 (15) (16) (17) (18) . Traditionally, VEGFRs were thought to be expressed on the surface of tumor endothelial cells, but not on tumor cells (18) (19) (20) . However, recent studies suggest that tumor-derived VEGF provides not only paracrine survival cues for endothelial cells, but may also fuel autocrine processes in gliomas cells (tumor-secreted VEGF providing prosurvival signaling through VEGFRs expressed by tumor cells or BTSCs themselves) and play a role in tumor resistance to existing therapies (21) (22) (23) (24) .
However, the direct effect of VEGF on biological behavior of BTSCs has not been completely elucidated. In this study, we established C6 glioma stem cells (C6GSCs), and then the VEGF expression of C6GSCs was downregulated by lentiviral vector-VEGF short hairpin RNA (shRNA). The proliferation, differentiation and invasion of C6GSCs were detected by an inverted phase contrast microscope, flow cytometry and immunofluorescence.
Materials and methods
Isolation and identification of C6GSCs. C6 glioma cells were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were cultured in the serum containing medium composed of Dulbecco's modified Eagle's medium (DMEM) with high glucose and 10% fetal bovine serum. Cells that were in the exponential growth phase were then collected and transplanted to a new culture flask with an equal volume of serum-free neural stem cell (NSC) medium containing DMEM/F12 with 2% B27, epidermal growth factor (EGF, 10 ng/ml) and basic fibroblast growth factor (bFGF, 10 ng/ml). Cells were incubated at 37˚C with 95% air, 5% CO 2 and 100% humidity. Two weeks later, floating primary tumor spheres were collected. The sphere cells were harvested, dissociated into single cells, and plated into a 96-well plate for the subsphere-forming assay by limiting dilution as described previously (25) . In brief, the cells in single-cell suspension were diluted to one cell per microliter and plated at one to two cells per well. Cells were fed with 200 µl serum-free media with growth factors, changing half of the medium every 5 days. After plating, the cells were observed, and only wells containing a single cell were considered.
Subspheres from one mother cell were characterized by immunocytochemistry against anti-CD133 antibody (1:400, Roche, Germany) or anti-nestin antibody (1:1,000, Chemicon) as described previously. In brief, the subspheres were incubated with primary antibodies: rat anti-CD133, mouse monoclonal anti-nestin overnight at 4˚C, followed by incubation with Alexa Fluor 568-conjugated goat anti-rat (1:1,000, Molecular Probes), 488-conjugated goat anti-mouse (1:800, invitrogen). Cell nuclei were counter-stained with Hoechst 33342 for 30 min at room temperature (RT). Immunopositive cells were observed using a fluorescent microscope.
Construction and identification of shRNA lentiviral vector targeting rat VEGF. Four self-complementary hairpin DNA oligos targeting rat VEGF mRNA were designed by using Dharmagon siDESIGN Center algorithrm (http://www.dharmacon.com/ DesignCenter/DesignCenterPage.aspx) as follows: VEGF shRNA1 is 5'-TGCGGATCAAACCTCACC AAA-3'; VEGF shRNA2 is 5'-GAGCGGAGAAAGCATTTG TTT-3'; VEGF shRNA3 is 5'-GCGAGGCAGCTTGAGTTA AAC-3'; VEGF shRNA4 is 5'-GCCTCTGAAACCATGAAC TTT-3' , including a 9-nt loop sequences. Also, a mock sequence that lacks any similarity to the rat sequence was designed and synthetized. Lentiviral vectors for rat VEGF shRNA encoding a green fluorescent protein (GFP) sequence and a puromycin resistance gene was constructed by GenePharma (Shanghai, China), named as pGLVH1/GFP/PURO. DNA oligos were annealed and inserted in the rat H1 promoter site of the PGLVH1-GFP vector. Then, the RNA interference (RNAi) cassette was cloned into the latter vector and lentiviral vectors expressing shRNA were constructed. They were then confirmed by DNA sequencing identification.
Lentiviral vector DNAs and packaging vectors (pHelper1.0, pHelper2.0) (Qiagen) were then transfected into 293T cells. After transfection, the cells were incubated at 32˚C to increase viral titer. Forty-eight hours later, the supernatant containing the retroviral particles was collected, filtered through the 0.45-µm low protein binding syringe filter and the titer of lentivirus was determined.
C6GSCs were maintained in above mentioned medium and were plated into 6-well plates at 4x10 5 cells/well. Twenty-four hours later, the cells were transfected with viral supernatants in the presence of polybrene (6 µg/ml final concentration) for 12 h at a multiplicity of infection (MOI) of 10 and 20, then replaced with a fresh medium containing 5 µg/ml puromycin. After 72 h, the cells had been transfected for the subsequent study.
Semiquantitative RT-PCR analysis. Total RNA was extracted from 1x10 6 transfected cells in each group using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and 2 µg of total RNA was reverse transcribed into cDNA with oligo dT primers using Omniscript reverse transcriptase (Qiagen, Hilden, Germany) according to the manufacture's protocol. Hot start PCR was performed to analyze expression levels with the following primers. VEGF: sense 5'-GACCCTGGTGGAC ATCTTCCAGGA-3' and antisense 5'-GGTGAGAGGTCTAG TTCCCGA-3'. GAPDH: sense 5'-TGATGACATCAAGAAG GTGGTGAAG-3' and antisense 5'-TCCTTGGAGGCCAT GTGGGCCAT-3'.
The PCR products were subjected to agarose gel electrophoresis followed by staining with ethidium bromide. The band optical density of VEGF, relative to that of GAPDH (internal control) was quantified by image analysis system (Leica Q550I W, Cambridge, UK).
Western blot analysis. Western blot analysis was performed for whole cell lysate. Aliquots of total protein (50 µg per lane) were electrophoresed on a 12% SDS-polyacrylamide gradient gel and transferred to nitrocellulose membranes (Millipore). Washed in rinse buffer at RT and incubated in blocking buffer (5% fat-free milk in rinse buffer) for 30 min, the membranes were incubated for 2 h at RT with antibody. Further washed with rinse buffer, the membranes were incubated with 1:1,000 diluted HRP-conjugated secondary antibody (Santa Cruz) for 2 h at RT, followed by developing with enhanced chemiluminescence reagents (Amershame, Little Chalfont Buckinghamshire, UK). In addition, β-actin was used as a reference protein. The optical densities were analyzed by using ImageMaster™2D Platinum (Version 5.0, Amersham Biosciences, Piscataway, NJ, USA).
Proliferation assay of C6GSCs. The non-transfected C6GSCs (control group), mock transfected C6GSCs (mock group) and lentiviral vector-VEGF shRNA1 transfected C6GSCs (silence group) were cultured in the above mentioned medium. Photomicrographs were taken by an inverted phase contrast microscope and the size of cell spheres was analyzed. At 7 days in vitro (DIV), some cell spheres of three groups were dissociated into single-cell suspension mechanically by trypsin digestion. Collected cells were washed once in cold phosphate-buffered saline (PBS). The cells were fixed in 70% ethanol, treated with 100 mg/l RNase at 37˚C for 30 min and stained with 50 mg/l propidium iodide (Sigma) for 30 min. The cells were analyzed using flow cytometry (Epics XL; Beckman Coulter, Fullerton CA, USA).
Differentiation assay of C6GSCs. C6GSCs of three groups (1x10 5 cells/ml) were plated onto poly-D-lysine coated cover slips in 24-well plates containing serum-free medium, respectively. After 7 DIV, cells were fixed with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for 1 h, blocked in 5% goat serum for 30 min at RT and then incubated for 12 h at RT with primary antibodies. After washing three times in PBS, the cells were incubated in secondary antibodies for 6 h at RT. Antibodies were as follows: the primary monoclonal antibodies were against mouse microtubule Invasion assay of C6GSCs. C6GSCs of three groups (1x10 5 cells/ml) were added to the upper chamber of the Transwell. The lower chamber was filled with DMEM/F12 medium. After incubation for 12 h at 37˚C, the cells were fixed with 4% PFA for 30 min and stained with Hoechst 33342 for 30 min at RT. The filters were then rinsed thoroughly in distilled water and checked by bright field microscopy to ensure that the cells were adherent and had migrated. The non-migrating cells were then removed from the upper surface (inside) of the Transwell with a wet cotton swab.
Statistical analysis. Images were analyzed by Leica Qwin image processing and analysis software (Leica imaging system, Cambridge, UK). Statistical analysis was performed using statistics package for social science 16.0 (SPSS 16.0). Data are presented as mean ± standard deviation (M ± SD). Statistical comparisons were performed using one-way analysis of variance (ANOVA) and differences at P<0.05 were considered statistically significant.
Results

Identification of C6GSCs
. The C6 cells were cultured in serum-free NSC medium, and many formed floating primary tumor spheres. Subspheres from one mother cell were CD133 and nestin double-positive. The nestin fluorescence intensity of the C6GSC sphere of the silence group was lower than that of the other two groups (Fig. 1) .
Lentivirus-mediated RNAi inhibits VEGF expression in
C6GSCs. In order to exclude an off-target silencing effect mediated by specific shRNA, we employed 4 different sequences of VEGF shRNA. Lentiviral infection efficiency was calculated by GFP expression under a fluorescence microscope. The infection efficiency of lentiviral vectorshRNA was 98.02±1.37% when MOI was 1:20 ( Fig. 2) . To evaluate the inhibition of VEGF mRNA expression, semiquantitative RT-PCR was performed 72 h after infection, the VEGF mRNA expression in lentiviral vector-VEGF shRNA1 transfected C6GSCs was reduced by ~75%, as compared with the non-transfected and mock transfected ones (P<0.05). In addition, no difference was observed among the non-transfected cells, the mock-infected cells, and VEGF shRNA2, 3 and 4 transfected cells (Fig. 3) , indicating that the corresponding mRNA sequence for VEGF shRNA1, not VEGF shRNA2, 3 and 4 is specific RNAi target. Western blot analysis was also performed 72 h after infection. The VEGF protein expression demonstrated a significant reduction in lentiviral vector-VEGF shRNA1 transfected C6GSCs, as compared with non-transfected cells and mock transfected cells (P<0.05) (Fig. 4) , suggesting that VEGF shRNA1 strongly blocked VEGF expression, whereas no obvious inhibition of VEGF protein was observed in VEGF shRNA2, 3 and 4 transfected cells.
Proliferation of C6GSCs. The C6GSCs of 3 groups were cultured under the same conditions outlined in Materials and methods. The appearance of the sphere of three kinds of stem cells is similar at the beginning, showing a small and uniform cell sphere (Fig. 5A-C) . In the following days in culture, nontransfected C6GSCs and mock transfected C6GSC spheres grew significantly faster and reached a larger size than lentiviral vector-VEGF shRNA1 transfected C6GSC spheres (Fig. 5D-I) . At 7 DIV, the proliferation of lentiviral vector-VEGF shRNA1 transfected C6GSCs reached the peak. On the contrary, the other two groups proliferated continually and the diameter of a cell sphere was up to ~236.6820.43 and 240.8520.52 µm (Fig. 5J) . Flow cytometry also indicated that proliferation index of lentiviral vector-VEGF shRNA1 transfected C6GSCs were lower than that of the other two groups (Fig. 6) . 
Differentiation of
Invasion of C6GSCs.
Cell invasion is a characteristic feature of carcinoma cells. To investigate the role of VEGF in tumor cell invasion, we measured the ability of C6GSCs to invade through Matrigel-coated filters in a Transwell chamber assay. After transfected with VEGF shRNA1, the invasive cells were obviously decreased compared with the other two groups. However, there were no significant differences between the other two groups (Fig. 9 ).
Discussion
Gliomas are characterized by high morphological, genetic, and phenotypic heterogeneity. However, studies performed simply on bulk glioma cells yield limited information on its origin and the mechanisms which mediate its growth and progression. Encouragingly, by applying the methods used to study normal NSCs to brain tumor cells, many researcher have reported there were BTSCs in brain gliomas of different grades from both children and adults (26) (27) (28) (29) (30) (31) . BTSCs possess the ability to self-renew and to give rise to a variety of proliferating and differentiated cells that make up the brain tumor mass. BTSCs play an important role in resistance to radiotherapy and chemotherapy (32, 33) , angiogenesis (34) and metastasis (35) . However, their source and molecular signal pathways are still not fully understood.
There have been only a few successful isolations of BTSCs from established cell lines such as the human U373, A172 and U87 glioma cell lines (36) (37) (38) . Although the rat glioma cell line C6 is widely used in the study of gliomas, there is still controversy over the culture methods for BTSCs. The pioneering studies suggested cell surface markers such as CD133 (a cell surface marker for normal NSCs) and nestin (a cytoskeleton protein associated with NSCs and progenitor cells in central nervous system development) are recommended for the specific identification of BTSCs (28, 30, 39, 40) . In this study, the C6 cell line was cultured in a simplified serum-free NSC medium, in which a fraction of C6 cells could form stem cell spheres. The C6GSC spheres were CD133 and nestin double-positive.
Direct evidence shows that gliomas and BTSCs express high levels of VEGF (8) (9) (10) (11) . In this study, RT-PCR and western blot analysis showed that also the C6GSCs could express VEGF. Traditionally, it is thought VEGF secreted by tumor cells interacts with VEGFRs expressed on the surface of tumor endothelial cells, but not on tumor cells (18) (19) (20) and promote the migration, growth and survival of endothelial cells (12) (13) (14) . Recent studies suggest that tumor cells or BTSCs could express VEGFRs themselves (21) (22) (23) (24) . However, the direct effect of VEGF on biological behavior of BTSCs has not been completely elucidated.
We suggest that VEGF may be a key factor influencing the characteristics of C6GSCs. RNAi is highly specific and efficient in inhibiting target genes and is the focus of recent studies to make it a new tool for curing tumor, infectious and hereditary diseases (41) . In this study, lentiviral vector-VEGF shRNA was constructed to target the VEGF genes in the C6GSCs. After 72-h transfection, the VEGF mRNA expression in lentiviral vector-VEGF shRNA1 transfected C6GSCs was reduced by ~75%. Compared to control and mock groups, the ability of cell proliferation of lentiviral vector-VEGF shRNA1 transfected C6GSCs was decreased significantly and GFAP, MAP-2-positive cells were nestin-negative, which indicated that the ability of differentiation was enhanced. After transfected with VEGF shRNA1, the invasive cells were obviously decreased compared with the other two groups through Matrigel-coated filters in a Transwell chamber assay. All the data demonstrate that downregulation of VEGF expression attenuates malignant biological behavior of C6GSCs. RNAi of VEGF expression implies an effective anti-glioma strategy. Figure 9 . The invasion activity of C6GSCs was determined by Transwell chamber assay. After 12 h, the cells under the chamber were stained with Hoechst 33342. The invasive cells in the silence group were obviously decreased compared with the other two groups. However, there were no significant differences between the other two groups.
* vs. control P<0.05; # vs. mock P<0.05.
